The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
Helna Pettersson(NU Hospital Group), Julia Asp(Sahlgrenska University Hospital), Peter Johansson(Linköping University), Jenni Adamsson(University of Gothenburg), Lars Palmqvist(Sahlgrenska University Hospital), Björn Andréasson(NU Hospital Group), Staffan Nilsson(Chalmers University of Technology)
Cited by 2
Related Papers
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
|Journal of Clinical Oncology|2011|244
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis
|Journal of Neurology|2010|192